Clinical Trial 45408

Kirkland, WA 98034


Study 45403 Flyer

Have You or Someone You Know Been Diagnosed with Alzheimer’s Disease?

The ACT-AD trial is evaluating if a new investigational drug (ATH-1017) is safe and effective in improving symptoms of mild to moderate Alzheimer’s disease. ATH-1017 is designed to boost a repair and regenerative pathway for brain cells, promoting brain health and function. ATH-1017 represents a new approach to treat Alzheimer’s disease, potentially targeting the root cause of memory decline by repairing brain cells and rebuilding brain networks.

  • Study participation and study drug are free to all participants enrolled in the study
  • You may receive a stipend to compensate for time and effort for study participation including meals, travel, etc.

You or someone you know may be eligible if you:

  • Are between 55 and 85 years of age
  • Have been diagnosed with Alzheimer’s disease
  • Have a reliable support person or caregiver who is willing to participate in study visits, report on daily activities and oversee or help you with taking ATH-1017

* The safety and efficacy of ATH-1017 for the treatment of mild to moderate Alzheimer’s has not been previously established. Talk to your doctor about participating in Athira’s clinical trials of ATH-1017.

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.